These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 34887111)
1. Bempedoic acid as a PPARα activator: new perspectives for hepatic steatosis treatment in a female rat experimental model. Bentanachs R; Velázquez AM; Sánchez RM; Alegret M; Laguna JC; Roglans N Clin Investig Arterioscler; 2022; 34(2):57-67. PubMed ID: 34887111 [TBL] [Abstract][Full Text] [Related]
3. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα). Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610 [TBL] [Abstract][Full Text] [Related]
4. [PPARβ/δ Activation prevents hypertriglyceridemia caused by a high fat diet. Involvement of AMPK and PGC-1α-Lipin1-PPARα pathway]. Barroso E; Astudillo AM; Balsinde J; Vázquez-Carrera M Clin Investig Arterioscler; 2013; 25(2):63-73. PubMed ID: 23849213 [TBL] [Abstract][Full Text] [Related]
5. Impairment of hepatic Stat-3 activation and reduction of PPARalpha activity in fructose-fed rats. Roglans N; Vilà L; Farré M; Alegret M; Sánchez RM; Vázquez-Carrera M; Laguna JC Hepatology; 2007 Mar; 45(3):778-88. PubMed ID: 17326204 [TBL] [Abstract][Full Text] [Related]
6. Effect of Creosote Bush-Derived NDGA on Expression of Genes Involved in Lipid Metabolism in Liver of High-Fructose Fed Rats: Relevance to NDGA Amelioration of Hypertriglyceridemia and Hepatic Steatosis. Zhang H; Li Y; Hu J; Shen WJ; Singh M; Hou X; Bittner A; Bittner S; Cortez Y; Tabassum J; Kraemer FB; Azhar S PLoS One; 2015; 10(9):e0138203. PubMed ID: 26394137 [TBL] [Abstract][Full Text] [Related]
7. ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score. Sanjay KV; Vishwakarma S; Zope BR; Mane VS; Mohire S; Dhakshinamoorthy S Curr Res Pharmacol Drug Discov; 2021; 2():100051. PubMed ID: 34909677 [TBL] [Abstract][Full Text] [Related]
8. The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation. Barroso E; Rodríguez-Calvo R; Serrano-Marco L; Astudillo AM; Balsinde J; Palomer X; Vázquez-Carrera M Endocrinology; 2011 May; 152(5):1848-59. PubMed ID: 21363937 [TBL] [Abstract][Full Text] [Related]
9. Fructose supplementation impairs rat liver autophagy through mTORC activation without inducing endoplasmic reticulum stress. Baena M; Sangüesa G; Hutter N; Sánchez RM; Roglans N; Laguna JC; Alegret M Biochim Biophys Acta; 2015 Feb; 1851(2):107-16. PubMed ID: 25463011 [TBL] [Abstract][Full Text] [Related]
10. Betaine prevented fructose-induced NAFLD by regulating LXRα/PPARα pathway and alleviating ER stress in rats. Ge CX; Yu R; Xu MX; Li PQ; Fan CY; Li JM; Kong LD Eur J Pharmacol; 2016 Jan; 770():154-64. PubMed ID: 26593707 [TBL] [Abstract][Full Text] [Related]
11. KHK, PNPLA3 and PPAR as Novel Targets for the Anti-Steatotic Action of Bempedoic Acid. Velázquez AM; Bentanachs R; Sala-Vila A; Lázaro I; Rodríguez-Morató J; Sánchez RM; Laguna JC; Roglans N; Alegret M Biomedicines; 2022 Jun; 10(7):. PubMed ID: 35884822 [TBL] [Abstract][Full Text] [Related]
12. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells. Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265 [TBL] [Abstract][Full Text] [Related]
13. Bempedoic Acid Unveils Therapeutic Potential in Non-Alcoholic Fatty Liver Disease: Suppression of the Hepatic PXR-SLC13A5/ACLY Signaling Axis. Sun Q; Guo Y; Hu W; Zhang M; Wang S; Lei Y; Meng H; Li N; Xu P; Li Z; Lin H; Huang F; Qiu Z Drug Metab Dispos; 2023 Dec; 51(12):1628-1641. PubMed ID: 37684055 [TBL] [Abstract][Full Text] [Related]
14. Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action. Roglans N; Laguna JC; Alegret M Curr Opin Lipidol; 2023 Aug; 34(4):141-146. PubMed ID: 36942869 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats. Li S; Liao X; Meng F; Wang Y; Sun Z; Guo F; Li X; Meng M; Li Y; Sun C PLoS One; 2014; 9(1):e86724. PubMed ID: 24489777 [TBL] [Abstract][Full Text] [Related]
16. Resveratrol prevents hepatic steatosis and endoplasmic reticulum stress and regulates the expression of genes involved in lipid metabolism, insulin resistance, and inflammation in rats. Pan QR; Ren YL; Liu WX; Hu YJ; Zheng JS; Xu Y; Wang G Nutr Res; 2015 Jul; 35(7):576-84. PubMed ID: 26055348 [TBL] [Abstract][Full Text] [Related]
18. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway. Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696 [TBL] [Abstract][Full Text] [Related]
19. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα. Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923 [TBL] [Abstract][Full Text] [Related]
20. Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats. Zhao X; Xue J; Wang XL; Zhang Y; Deng M; Xie ML Int Immunopharmacol; 2014 Sep; 22(1):176-81. PubMed ID: 24993341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]